Product image of Kineret (Anakinra) supplied by GNH India

Kineret

Active Ingredient:
Anakinra
Origin:
EU

Kineret (Anakinra)

Anakinra, the active ingredient in Kineret, is an interleukin‑1 receptor antagonist presented as a 100 mg/0.67 mL injectable solution for subcutaneous use. It treats rheumatoid arthritis and several autoinflammatory conditions in adults and children, including CAPS, NOMID, systemic juvenile idiopathic arthritis and gout flares.

GNH India supplies Kineret as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Swedish Orphan Biovitrum Ab (Publ)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kineret is an interleukin‑1 pathway inhibitor used in several inflammatory and autoinflammatory diseases.

  • Rheumatoid arthritis: reduces signs and symptoms of disease activity in adult patients.
  • Cryopyrin‑Associated Periodic Syndromes (CAPS): controls recurrent fever and systemic inflammation.
  • Neonatal‑onset multisystem inflammatory disease (NOMID): mitigates chronic inflammatory manifestations.
  • Systemic juvenile idiopathic arthritis (SJIA): improves joint symptoms and systemic features.
  • Gout flares: provides rapid relief of acute inflammatory attacks.

How It Works

  • Anakinra competitively binds to the interleukin‑1 type I receptor, preventing endogenous IL‑1α and IL‑1β from engaging the receptor. This blocks downstream NF‑κB and MAPK signaling pathways that drive inflammatory gene expression, thereby reducing cellular activation, cytokine release, and tissue inflammation associated with IL‑1‑mediated diseases.

Side Effects

Adverse reactions may occur with Kineret therapy.

Common Side Effects

  • Injection site reactions: redness, swelling, or pain at the injection site.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal discomfort.
  • Upper respiratory tract infection: symptoms of cold or sinusitis.
  • Arthralgia: transient joint pain.
  • Rash: mild skin irritation.

Serious or Rare Side Effects

  • Neutropenia: significant reduction in neutrophil count.
  • Serious infections: bacterial, fungal, or viral infections requiring medical attention.
  • Hypersensitivity reactions: anaphylaxis, angioedema, or severe skin reactions.
  • Hepatitis: elevated liver enzymes or clinical hepatitis.
  • Malignancy: rare reports of cancer development.
  • Injection‑site abscess: localized infection requiring drainage.

Precautions & Warnings

Before initiating Kineret, clinicians should consider several safety measures.

  • Monitor infection risk: assess for active infections and advise patients to report new signs promptly.
  • Screen for neutropenia: obtain baseline and periodic complete blood counts.
  • Assess hypersensitivity: discontinue if severe allergic reactions occur.
  • Use caution in pregnancy: category B, weigh benefits against potential risks.
  • Adjust in renal impairment: dose may need modification in severe renal dysfunction.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Kineret may interact with other agents that affect immune function.

Major Interactions (Avoid)

  • Live attenuated vaccines: concurrent use can increase risk of vaccine‑derived infection.
  • Other IL‑1 antagonists: co‑administration may lead to excessive immunosuppression.

Moderate Interactions (Monitor Closely)

  • Corticosteroids: combined use may heighten infection susceptibility.
  • Methotrexate: may require enhanced hepatic monitoring.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor renal function and gastrointestinal tolerance.
  • Antimicrobial prophylaxis: adjust based on infection risk assessment.
  • Immunosuppressive biologics: observe for additive immunosuppressive effects.

Frequently Asked Questions

Kineret (anakinra) is indicated for rheumatoid arthritis, cryopyrin‑associated periodic syndromes (CAPS), neonatal‑onset multisystem inflammatory disease (NOMID), systemic juvenile idiopathic arthritis (SJIA), and acute gout flares. In each condition it helps reduce inflammation by blocking interleukin‑1 signaling.

Anakinra is a recombinant form of the human interleukin‑1 receptor antagonist. It binds competitively to the IL‑1 type I receptor, preventing IL‑1α and IL‑1β from activating the receptor. This inhibition stops downstream inflammatory pathways, lowering cytokine production and tissue inflammation.

The specific dose and frequency of Kineret are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal clinical benefit while monitoring safety.

Kineret is classified as pregnancy category B, indicating no evidence of risk in animal studies but insufficient human data. It should be used only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; a risk‑benefit assessment is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Kineret (anakinra) is a short‑acting IL‑1 receptor antagonist administered daily, whereas other agents such as canakinumab have longer half‑lives and are given less frequently. Choice of therapy depends on disease severity, patient preference, and safety considerations, with Kineret offering rapid onset and flexibility in dosing adjustments.

Kineret must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Kineret is supplied as a sterile injectable solution for subcutaneous injection. The medication is typically drawn into a syringe and injected into the abdomen, thigh, or upper arm, following aseptic technique and the prescriber’s instructions.

Serious risks include neutropenia, which can predispose to severe infections, and rare hypersensitivity reactions such as anaphylaxis. Patients should be monitored regularly for signs of infection, blood count changes, and any allergic symptoms, and treatment should be stopped if severe reactions occur.

Kineret is contraindicated in patients with known hypersensitivity to anakinra or any component of the formulation. It should also be avoided in individuals receiving live attenuated vaccines concurrently, and used with caution in those with active serious infections or severe renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Anakinra

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT